Delayed release on October 24, 2026 of the Friday, October 23 edition. News and relative-date references are as of October 23.Novartis's investigational remibrutinib cut MS relapse rates 35.2% and 31.2% versus teriflunomide; Biokin's Bristol Myers Squibb/SystImmune-partnered iza-bren improved breast cancer PFS. Jazz/BeOne's Ziihera (zanidatamab), licensed from Zymeworks, has mature gastroesophageal survival data, while Tango reports pancreatic cancer responses with vopimetostat and Revolution Medicines' daraxonrasib. Johnson & Johnson's Tecvayli (teclistamab) moves earlier in European myeloma treatment, as we examine BMS's zola-cel safety in MS and Alnylam's brezosiran target engagement in Huntington's. Plus Bolt's Prana acquisition and Treasury's proposed biotech investment rules.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →